Global Oral Hypoglycemic Agents (OHAs) Market – Industry Trends and Forecast to 2030

Oral Hypoglycemic Agents (OHAs) Market Analysis and Size

Oral Hypoglycemic Medications are medications that are taken by mouth to manage blood sugar levels in people with type 2 diabetes. Diabetes is a metabolic disorder in which patients suffer from high blood glucose level than normal levels in an individual. These rises in blood sugar level are due to the body’s cells do not respond properly to insulin or due to inadequate insulin production. Diabetes is characterized by two types; insulin-dependent diabetes mellitus (type 1) and non-insulin-dependent diabetes mellitus (type 2). The most common symptoms of diabetes are increased thirst, frequent urination, weight and muscle loss, blurred vision, delayed wound healing, and fatigue. The increase in the prevalence of diabetes is an act at a major driver of the oral hypoglycemic agents (OHAs) market.

Data Bridge Market Research analyses that the Oral hypoglycemic agents (OHAs) Market which was USD 61.20 billion in 2022, would rocket up to USD 83.75 billion by 2030, and is expected to undergo a CAGR of 4.00% during the forecast period. “Metformin” dominates the type of product segment of the oral hypoglycemic agents (OHAs) market owing to their therapeutic efficacy and minimal side effects. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Oral Hypoglycemic Agents (OHAs) Market Scope and Segmentation

Market Definition

Oral hypoglycemic agents (OHAs) are medications used to manage and control blood sugar levels in individuals with diabetes. They are taken orally, making them a convenient treatment option for many patients. These drugs work by either increasing insulin production, improving insulin sensitivity, or reducing glucose production in the liver. They play a vital role in diabetes management, helping to prevent complications and maintain healthy blood sugar levels.

Oral Hypoglycemic Agents (OHAs) Market Dynamics

Drivers

• Increasing Prevalence of Diabetes

The global prevalence of diabetes is on the rise, primarily driven by factors such as sedentary lifestyles, unhealthy diets, and obesity. As the number of people diagnosed with diabetes increases, so does the demand for effective oral hypoglycemic agents. The expanding patient pool drives market growth for these medications.

• Technological Advancements

Continuous research and development in the field of diabetes management have led to the introduction of new and improved oral hypoglycemic agents. Technological advancements, such as the development of novel drug delivery systems, innovative formulations, and enhanced mechanisms of action, contribute to market growth by providing more effective and patient-friendly treatment options.

Opportunities

• Development of novel drug formulations

The market growth presents an opportunity for pharmaceutical companies to invest in the development of novel drug formulations. This includes extended-release formulations, combination therapies, and innovative drug delivery systems that enhance patient compliance, convenience, and efficacy.

Restraints/Challenges

• Limited Efficacy in Some Patients

While oral hypoglycemic agents are effective for many individuals with diabetes, they may not provide adequate glycemic control for all patients. Some individuals may require additional treatment modalities, such as insulin therapy or combination therapy. The limited efficacy in certain patient populations poses a challenge and highlights the need for personalized treatment approaches.

This Oral hypoglycemic agents (OHAs) Market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Oral hypoglycemic agents (OHAs) Market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2022, Novo Nordisk, a Danish company, announced the launch of oral semaglutide in India for the treatment of type 2 diabetes.

Oral hypoglycemic agents (OHAs) Market Scope

The oral hypoglycemic agents (OHAs) market is segmented on the basis of the type of product and end-users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type of Product

• Sulfonylureas
• Metformin
• Thiazolidinediones
• Alpha-Glucosidase Inhibitors
• Immunotherapy

End users

• Hospitals
• Clinics

Oral hypoglycemic agents (OHAs) Market Regional Analysis/Insights

The Oral hypoglycemic agents (OHAs) Market is analysed and market size insights and trends are provided by country, type of product and end users as referenced above.

The countries covered in the oral hypoglycemic agents (OHAs) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to account for the largest market share due to the increased consumption of oral hypoglycemic agents for the treatment of diabetes.

Asia-Pacific is expected to account for the fastest growing market and is expected to account for the largest market share over coming years for the oral hypoglycemic agents (OHAs) market due to the rising prevalence of diabetes.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The oral hypoglycemic agents (OHAs) market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kind of products for oral hypoglycemic agents (OHAs) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the oral hypoglycemic agents (OHAs) market. The data is available for the historic period 2015-2020.

Competitive Landscape and Oral hypoglycemic agents (OHAs) Market Share Analysis

The oral hypoglycemic agents (OHAs) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the oral hypoglycemic agents (OHAs) market.

Some of the major players operating in the oral hypoglycemic agents (OHAs) market are:

• Sanofi (France)
• Ganlee (China)
• Biocon (India)
• Novo Nordisk A/S (Denmark)
• Eli Lilly and Company (U.S.)
• Tonghua Dongbao Pharmaceutical Co., Ltd. (China)
• Wanbang Biopharmaceuticals (China)
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• Takeda Pharmaceuticals Limited (Japan)
• Merck Sharp & Dohme Corp. (MSD) (U.S.)
• AstraZeneca (U.K.)
• Janssen Global Services, LLC (a subsidiary of Johnson & Johnson) (Belgium)
• Boehringer Ingelheim Ltd. (Germany)

SKU-59295